2-phenylindolone has been researched along with Lung Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Hu, G; Kuai, M; Li, Q; Liu, R; Lv, M; Su, Q; Tu, Z; Yang, X; Ye, S; Yu, Z; Yuan, H | 1 |
1 other study(ies) available for 2-phenylindolone and Lung Neoplasms
Article | Year |
---|---|
Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives.
Topics: A549 Cells; Amination; Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Drug Design; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; raf Kinases; Signal Transduction | 2019 |